A roadmap for cost-of-goods planning to guide economic production of cell therapy products

Published:September 18, 2017DOI:


      Cell therapy products are frequently developed and produced without incorporating cost considerations into process development, contributing to prohibitively costly products. Herein we contextualize individual process development decisions within a broad framework for cost-efficient therapeutic manufacturing. This roadmap guides the analysis of cost of goods (COG) arising from tissue procurement, material acquisition, facility operation, production, and storage. We present the specific COG considerations related to each of these elements as identified through a 2013 International Society for Cellular Therapy COG survey, highlighting the differences between autologous and allogeneic products. Planning and accounting for COG at each step in the production process could reduce costs, allowing for more affordable market pricing to improve the long-term viability of the cell therapy product and facilitate broader patient access to novel and transformative cell therapies.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic and Personal
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Cytotherapy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Ledford H.
        Immune cells boost cancer survival from months to years.
        Nature. 2014; 516: 156
        • Palmer E.
        Novartis and others face higher manufacturing costs with CAR-T cell treatments.
        • Plumridge H.
        New Costly Cancer Treatments Face Hurdles Getting to Patients.
        (Wall Street Journal)2014
        • Ward A.
        Race to control costs of cancer therapy revolution.
        (Financial Times)2015
        • Palmer E.
        Manufacturing costs loom large for personalized CAR-T cancer meds and their need for speed.
        • Crabb N.S.
        • Stevens A.
        Exploring the assessment and appraisal of regenerative medicines and cell therapy products.
        (Centre for Health Technology Evaluation, Centre for Health Technology Evaluation, National Institute for Health and Care Excellence; Available from:)
        • Abou-El-Enein M.
        • Romhild A.
        • Kaiser D.
        • Beier C.
        • Bauer G.
        • Volk H.D.
        • et al.
        Good Manufacturing Practices (GMP) manufacturing of advanced therapy medicinal products: a novel tailored model for optimizing performance and estimating costs.
        Cytotherapy. 2013; 15: 362-383
        • Simaria A.S.
        • Hassan S.
        • Varadaraju H.
        • Rowley J.
        • Warren K.
        • Vanek P.
        • et al.
        Allogeneic cell therapy bioprocess economics and optimization: single-use cell expansion technologies.
        Biotechnol Bioeng. 2014; 111: 69-83
        • Hassan S.
        • Simaria A.S.
        • Varadaraju H.
        • Gupta S.
        • Warren K.
        • Farid S.S.
        Allogeneic cell therapy bioprocess economics and optimization: downstream processing decisions.
        Regen Med. 2015; 10: 591-609
        • Hassan S.
        • Huang H.
        • Warren K.
        • Mahdavi B.
        • Smith D.
        • Jong S.
        • et al.
        Process change evaluation framework for allogeneic cell therapies: impact on drug development and commercialization.
        Regen Med. 2016; 11: 287-305
        • Lipsitz Y.Y.
        • Timmins N.E.
        • Zandstra P.W.
        Quality cell therapy manufacturing by design.
        Nat Biotech. 2016; 34: 393-400
        • Flommersfeld S.
        • Bakchoul T.
        • Bein G.
        • Wachtel A.
        • Loechelt C.
        • Sachs U.J.
        A single center comparison between three different apheresis systems for autologous and allogeneic stem cell collections.
        Transfus Apher Sci. 2013; 49: 428-433
        • Brauninger S.
        • Bialleck H.
        • Thorausch K.
        • Felt T.
        • Seifried E.
        • Bonig H.
        Allogeneic donor peripheral blood “stem cell” apheresis: prospective comparison of two apheresis systems.
        Transfusion. 2012; 52: 1137-1145
        • Moog R.
        • Muller N.
        Technical aspects and performance in collecting peripheral blood progenitor cells.
        Ann Hematol. 1998; 77: 143-147
        • Remberger M.
        • Ringden O.
        • Mattsson J.
        Bone marrow aspiration technique has deteriorated in recent years.
        Bone Marrow Transplant. 2015; 50: 1007-1009
        • Dzieciatkowska M.
        • D'Alessandro A.
        • Burke T.A.
        • Kelher M.R.
        • Moore E.E.
        • Banerjee A.
        • et al.
        Proteomics of apheresis platelet supernatants during routine storage: gender-related differences.
        J Proteomics. 2015; 112: 190-209
        • Panch S.R.
        • Yau Y.Y.
        • Fitzhugh C.D.
        • Hsieh M.M.
        • Tisdale J.F.
        • Leitman S.F.
        Hematopoietic progenitor cell mobilization is more robust in healthy African American compared to Caucasian donors and is not affected by the presence of sickle cell trait.
        Transfusion. 2016; 56: 1058-1065
        • Baimukanova G.
        • Miyazawa B.
        • Potter D.R.
        • Muench M.O.
        • Bruhn R.
        • Gibb S.L.
        • et al.
        Platelets regulate vascular endothelial stability: assessing the storage lesion and donor variability of apheresis platelets.
        Transfusion. 2016; 56: 13532
        • Mendicino M.
        • Bailey A.M.
        • Wonnacott K.
        • Puri R.K.
        • Bauer S.R.
        MSC-based product characterization for clinical trials: an FDA perspective.
        Cell Stem Cell. 2014; 14: 141-145
        • Hourd P.
        • Ginty P.
        • Chandra A.
        • Williams D.J.
        Manufacturing models permitting roll out/scale out of clinically led autologous cell therapies: regulatory and scientific challenges for comparability.
        Cytotherapy. 2014; 16: 1033-1047
        • Carpenter M.K.
        • Couture L.A.
        Regulatory considerations for the development of autologous induced pluripotent stem cell therapies.
        Regen Med. 2010; 5: 569-579
        • Food and Drug Administration
        Minimal Manipulation of Human Cells, Tissues, and Cellular and Tissue-Based Products: Draft Guidance for Industry and Food and Drug Administration Staff.
        (Available from:)
        • Brandes R.
        Aseptic Processing: Qualification of personnel. vol. 12. Maas and Peithner GMP Publishing, Schopfheim, Germany2012
        • Food and Drug Administration
        Current Good Manufacturing Practice for Finished Pharmaceuticals.
        (Available from:)
        • Kirouac D.C.
        • Zandstra P.W.
        The systematic production of cells for cell therapies.
        Cell Stem Cell. 2008; 3: 369-381
        • Rowley J.
        • Abraham E.
        • Campbell A.
        • Brandwein H.
        • Oh S.
        Meeting lot-size challenges of manufacturing adherent cells for therapy.
        Bioprocess Int. 2012; 10: 16-22
        • Schilling M.A.
        • Esmundo M.
        Technology S-curves in renewable energy alternatives: analysis and implications for industry and government.
        Energy Policy. 2009; 37: 1767-1781
        • Stacey G.N.
        • Masters J.R.
        Cryopreservation and banking of mammalian cell lines.
        Nat Protoc. 2008; 3: 1981-1989
        • Ginis I.
        • Grinblat B.
        • Shirvan M.H.
        Evaluation of bone marrow-derived mesenchymal stem cells after cryopreservation and hypothermic storage in clinically safe medium.
        Tissue Eng Part C Methods. 2012; 18: 453-463
        • Davies O.G.
        • Smith A.J.
        • Cooper P.R.
        • Shelton R.M.
        • Scheven B.A.
        The effects of cryopreservation on cells isolated from adipose, bone marrow and dental pulp tissues.
        Cryobiology. 2014; 69: 342-347
        • Morris C.
        • de Wreede L.
        • Scholten M.
        • Brand R.
        • van Biezen A.
        • Sureda A.
        • et al.
        Should the standard dimethyl sulfoxide concentration be reduced? Results of a European Group for Blood and Marrow Transplantation prospective noninterventional study on usage and side effects of dimethyl sulfoxide.
        Transfusion. 2014; 54: 2514-2522
        • Al-Saqi S.H.
        • Saliem M.
        • Quezada H.C.
        • Ekblad Å.
        • Jonasson A.F.
        • Hovatta O.
        • et al.
        Defined serum- and xeno-free cryopreservation of mesenchymal stem cells.
        Cell Tissue Bank. 2015; 16: 181-193
        • Hanley P.J.
        • Mei Z.
        • da Graca Cabreira-Hansen M.
        • Klis M.
        • Li W.
        • Zhao Y.
        • et al.
        Manufacturing mesenchymal stromal cells for phase I clinical trials.
        Cytotherapy. 2013; 15: 416-422
        • Badowski M.
        • Muise A.
        • Harris D.T.
        Mixed effects of long-term frozen storage on cord tissue stem cells.
        Cytotherapy. 2014; 16: 1313-1321
        • Bissoyi A.
        • Pramanik K.
        Role of the apoptosis pathway in cryopreservation-induced cell death in mesenchymal stem cells derived from umbilical cord blood.
        Biopreserv Biobank. 2014; 12: 246-254